Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Equities researchers at Oppenheimer lowered their Q1 2018 earnings estimates for Intercept Pharmaceuticals in a report issued on Thursday, Zacks Investment Research reports. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will post earnings per share of ($3.34) for the quarter, down from their prior forecast of ($3.07). Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for Intercept Pharmaceuticals’ Q2 2018 earnings at ($3.44) EPS, Q3 2018 earnings at ($3.19) EPS, Q4 2018 earnings at ($3.48) EPS, FY2018 earnings at ($13.45) EPS, FY2019 earnings at ($8.18) EPS, FY2020 earnings at ($5.76) EPS, FY2021 earnings at ($2.86) EPS and FY2022 earnings at ($0.66) EPS.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($3.39) by ($1.04). The business had revenue of $37.69 million for the quarter, compared to analysts’ expectations of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 267.95% and a negative net margin of 275.18%. The firm’s quarterly revenue was up 173.1% on a year-over-year basis. During the same period last year, the firm earned ($4.84) earnings per share.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down $0.19 during midday trading on Monday, reaching $66.11. The company’s stock had a trading volume of 474,801 shares, compared to its average volume of 918,584. The stock has a market cap of $1,660.00, a P/E ratio of -4.60 and a beta of -1.92. The company has a debt-to-equity ratio of 21.71, a current ratio of 4.31 and a quick ratio of 4.31. Intercept Pharmaceuticals has a 12 month low of $51.05 and a 12 month high of $135.59.
Hedge funds have recently modified their holdings of the stock. IFP Advisors Inc increased its position in Intercept Pharmaceuticals by 90.9% in the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 1,182 shares during the period. PNC Financial Services Group Inc. increased its position in Intercept Pharmaceuticals by 23.3% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 470 shares during the period. Nomura Holdings Inc. acquired a new position in Intercept Pharmaceuticals during the 2nd quarter worth approximately $366,000. DSC Advisors L.P. acquired a new position in Intercept Pharmaceuticals during the 4th quarter worth approximately $204,000. Finally, Amalgamated Bank acquired a new position in Intercept Pharmaceuticals during the 4th quarter worth approximately $209,000. Hedge funds and other institutional investors own 74.33% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.